Traditionally tasked with providing technical and scientific assessments on the safety and efficacy of medicines and other monitored products, the Reviewing Commission (RC) now assumes additional responsibilities. These encompass suggesting initiatives to foster innovation for the betterment of public health, soliciting insights from external specialists (subject to a prior review of the Transfer of Value registry and Conflict Check), and championing the adoption of best practices.
Noteworthy adjustments have been made regarding the composition of the commission’s members, particularly of the Medicine Specialized Chambers (MSCs). Whereas previous agreements mandated that members of the MSCs must hold medical degrees or Pharm Ds (or possess expertise in biotechnology) and serve for a fixed term, the current directive allows for a more diversified selection. The majority of members can now be drawn from a National Registry of Experts established by INVIMA through a public tender process, followed by an assessment and qualification of the candidates. Experts included in this registry can serve for two-year terms.
The agreement stipulates that INVIMA reserves the right to occasionally deviate from the recommendations and opinions made by the Reviewing Commission, provided that such deviations are adequately justified.
